Massive Bio, GELL team up on AI and oncology research in Latin America

Massive Bio and the Latin American Study Group on Lymphoproliferative Disorders, or GELL, announced a strategic partnership on July 27, 2026, to expand clinical research, physician education, and AI adoption across Latin America and the U.S. The deal pairs GELL’s investigator network in more than 20 countries with Massive Bio’s AI platform to broaden access to precision oncology and clinical trials.

Why it matters: - The partnership aims to widen access to precision oncology and clinical trials across Latin America. - The collaboration could also improve how physicians identify patients, enroll them in studies, and use AI in treatment decisions. - The alliance links a major regional academic network with an AI-focused oncology platform, which could speed research and education across borders.

What happened: - Massive Bio and GELL announced a strategic partnership on July 27, 2026. - The collaboration will focus on clinical research, physician education, and innovation in Latin America and the U.S. - Massive Bio is based in Boca Raton, Florida. - GELL is a Latin American scientific and academic network focused on lymphomas and hematologic malignancies.

The details: - GELL brings investigators, hematologists, oncologists, and academic institutions from more than 20 countries. - Massive Bio contributes AI, real-world data, precision medicine, clinical trial recruitment, and healthcare technology. - The organizations plan to expand educational programs, scientific exchange, multicenter research, and access to innovative treatments. - Joint work will include educational programs, scientific forums, investigator meetings, and regional initiatives. - The partners want to build awareness and practical adoption of AI across healthcare provider networks. - The collaboration will also aim to strengthen ties among healthcare professionals, research centers, and academic institutions in Latin America. - The partnership creates new opportunities to engage physician and healthcare networks in the U.S. - Massive Bio said the collaboration should expand clinical trial access, strengthen scientific collaboration, and advance responsible use of AI across provider networks. - GELL said the partnership supports its mission of scientific collaboration, education, and research across Latin America. - GELL’s vice president said AI is becoming an increasingly important tool in modern hematology and oncology. - Massive Bio’s business development director said the alliance can accelerate innovation, education, collaboration, and patient access to cutting-edge treatment opportunities. - The companies said the broader goal is to improve outcomes for patients with hematologic malignancies and other cancers.

Between the lines: - The partnership reflects a push to make AI a routine part of oncology workflows, not just a research tool. - The U.S. connection could help Latin American investigators reach broader scientific and clinical networks. - The focus on education suggests adoption may be as important as technology in this deal.

What's next: - Massive Bio and GELL plan to roll out joint educational efforts and scientific forums. - The groups will look to support multicenter research initiatives and investigator engagement across the region. - The partnership is expected to deepen international cooperation around oncology research and AI use.

The bottom line: - Massive Bio and GELL are betting that shared research, education, and AI tools can expand access to precision cancer care across Latin America and the U.S. - More information is available at Massive Bio and GELL.